Clovis Oncology: Falls on lower Q1 product revenue
05/05/2021 14:07
** Drugmaker's shares CLVS.O fall 6.9% to $5.13 premarket
** Net product revenues of Clovis' cancer drug, Rubraca,
drops about 11% to $38.1 mln for the first-quarter, from a year
ago urn:newsml:reuters.com:*:nBw9XmkYma
** Says revenue hurt by fewer diagnoses and fewer patient
starts during the COVID-19 pandemic
** Reports narrower qtrly net loss of $66.3 mln vs $99.3 mln
in the yr-ago qtr
** CLVS had gained 14.8% YTD as of its last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber